Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.exelixis.com
Exelixis, Inc. News Releases
Get the latest updates from Exelixis, Inc. News Releases directly as they happen.
Follow now 114 followers
Latest posts
Last updated 6 days ago
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
6 days ago
– Conference Call and Webcast to Follow at 5:00 p.m. ET /...
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
8 days ago
– Zanzalintinib in combination with atezolizumab improved median overall survival to 10.9...
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
10 days ago
– CABOMETYX reduced the risk of disease progression or death by 81%...
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
about 2 months ago
– Dr. Aftab has served for over 25 years at Exelixis and...
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
2 months ago
– Presentations to be webcast on www.exelixis.com – ALAMEDA, Calif. --(BUSINESS WIRE)--Aug...
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
3 months ago
- Total Revenues of $568.3 million , Cabozantinib Franchise U.S. Net Product...
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
3 months ago
– Approval is based on the phase 3 CABINET pivotal trial, in...
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025
4 months ago
– Conference Call and Webcast to Follow at 5:00 p.m. ET /...
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
4 months ago
– Zanzalintinib in combination with atezolizumab demonstrated a statistically significant reduction in...
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
4 months ago
– A regulatory decision by the European Medicines Agency is anticipated in...
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025
5 months ago
– Zanzalintinib in combination with nivolumab demonstrated an objective response rate of...
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June
5 months ago
- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--May...